research Beard hair response in Alopecia Areata Universalis treated with baricitinib
Baricitinib effectively promotes beard regrowth in most men with alopecia areata universalis.
Search
for
Sort by
Research
990-1000 / 1000+ results
research 1077 Efficacy and safety of ENERGI-F701 solution versus 2% minoxidil solution for female pattern hair loss: a phase II, multi-center, randomized, double-blind, head-to-head, parallel trial
ENERGI-F701 solution was found to be more effective and safer than Regaine® 2% minoxidil solution in treating female pattern hair loss, with increased hair density and less side effects.
research Poly(γ-Glutamic Acid)/Chitosan Hydrogel Nanoparticles For Effective Preservation And Delivery Of Fermented Herbal Extract For Enlarging Hair Bulb And Enhancing Hair Growth
The nanoparticles effectively deliver herbal extract to enhance hair growth.
research JAK Inhibitors for Treatment of Alopecia Areata
JAK inhibitors can effectively reverse hair loss in people with alopecia areata.
research Spironolacton in dermatologischen Behandlungen
research Comparing the therapeutic effects of finasteride gel and tablet in treatment of the androgenetic alopecia
Finasteride gel is slightly more effective than the tablet for treating hair loss.
research Long-term efficacy and safety of the dual 5-alpha reductase blocker dutasteride on male androgenetic alopecia patients
Dutasteride effectively and safely treats male hair loss for over a year.
research FINASTERIDE AS A TREATMENT FOR MALE ANDROGENETIC ALOPECIA
Finasteride effectively treats male pattern baldness.
research Rationale and design of the GLADE study: a randomized, multicenter, double-blind, placebo-controlled trial evaluating the safety and efficacy of gestrinone subdermal bioabsorbable pellet in endometriosis-related pelvic pain
The GLADE study is a randomized, multicenter, double-blind, placebo-controlled trial designed to evaluate the safety and efficacy of gestrinone subdermal bioabsorbable pellets in treating pelvic pain related to endometriosis. It involves 100 participants with deep infiltrative endometriosis who did not respond satisfactorily to surgery. Participants are randomly assigned to receive either gestrinone pellets or a placebo, alongside a levonorgestrel-releasing intrauterine system, over a 6-month period. The primary endpoint is the occurrence of serious adverse events (SAEs) within 6 months, with additional evaluations on androgenization, laboratory changes, pelvic pain intensity, and quality of life. The study aims to provide insights into the safety, tolerability, and pharmacokinetics of gestrinone pellets, potentially informing clinical practice for endometriosis treatment.
research Nurses' Drug Alert
Some drugs can cause serious side effects, like hypoglycemia from mix-ups, skin reactions, or depression, and while penicillamine may help rheumatoid arthritis more than auranofin, it has more severe side effects.